81% Of China’s Generic Drug Applications Are Redundant
This article was originally published in PharmAsia News
Chinese authorities received 2,095 generic registration applications in 2012, more than 81% of them are for generic versions of branded drugs that already have multiple approved generics.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.